SecBot SecBot
PRESS-RELEASE ·Filed Nov 6, 2026

CGON

CG Oncology Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed10d 18h ago WireGlobeNewswire
Press release · Announcement
Actionable Insight • Neutral

The next major catalyst is PIVOT-006 topline data in November 2026, which could significantly impact the stock if positive or negative. Also watch for BLA submission completion in Q4 2026 and 12-month data from two cohorts in December 2026.

DirectionNeutral
Confidencehigh
Horizonweeks

cretostimogene

▲ Bullish Named in this press release
Impact
Phase
Phase 3
Time to market
BLA submission planned for Q4 2026 in BCG-unresponsive NMIBC. If accepted and approved under standard FDA review, potential approval could come in H2 2027. The drug already has Breakthrough Therapy designation from the FDA.
Next catalyst
None dated

What to watchWatch for BLA submission completion in Q4 2026, this is the key catalyst that will determine whether cretostimogene becomes the first FDA-approved oncolytic virus therapy for NMIBC. Also monitor PIVOT-006 Phase 3 topline data (intermediate-risk NMIBC), which could be imminent. The $1.05B ATM facility creates ongoing dilution overhang, so positive regulatory catalysts are needed to offset that pressure.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$75.99
T+0 close · Nov 6, 2026 · via day close
Latest settled
−2.09%
T+5 · $74.40
Vs SPY
−4.69%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $75.99entry
  2. T+1 · 8d ago −1.65%α −4.01% · $74.74
  3. T+5 · 4d ago −2.09%α −4.69% · $74.40
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CG Oncology reported Q3 2026 financial results showing a net loss of $56.9 million ($0.64 per share), widening from a $43.8 million loss a year ago, as R&D spending rose 41% to $39.2 million. The company highlighted upcoming key catalysts: PIVOT-006 Phase 3 topline data in November 2026, 12-month data from two cohorts in December 2026, and completion of a BLA submission for BCG-unresponsive NMIBC in Q4 2026. Cash of $984.5 million is sufficient through 2029.

Key Financial Metrics

Revenue
$1.6K
-3.7% YoY
EPS
$-0.64

Key Facts

  • Q3 2026 net loss of $56.9 million vs $43.8 million in Q3 2025
  • R&D expenses rose to $39.2 million from $27.9 million year-over-year
  • Cash, cash equivalents and marketable securities of $984.5 million as of September 30, 2026
  • PIVOT-006 Phase 3 topline data expected November 2026
  • BOND-003 Cohort P and CORE-008 Cohort CX 12-month data expected December 2026
  • BLA submission for BCG-unresponsive NMIBC expected to be completed Q4 2026
  • Appointed Isabel Kalofonos as Chief Commercial Officer in October 2026

Financial Impact

Net loss widened by $13.1 million year-over-year; cash burn of $57 million in Q3; cash runway through 2029

net lossR&D expensescash position

Risk Factors

  • PIVOT-006 topline data may not meet expectations or may differ from final results
  • BLA submission may face delays or FDA may not approve cretostimogene
  • Cash burn rate is increasing; actual runway may be shorter than estimated
  • Clinical trial results from one cohort may not be predictive of others

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3397495

Track record

25 reports on CGON

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 Now $84.78 −14.23% settles Dec 15
  2. Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 Now $84.78 −10.77% settles Dec 15
  3. Nov 6, 202610d ago 8-K Bearish 5/10 Entry $75.99 Now $84.78 −11.57% settles Dec 7
  4. Nov 6, 202610d ago Press Release Neutral 4/10 Viewing Entry $75.99 Now $84.78 +11.57% settles Dec 7
  5. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 Now $84.78 +32.34% settles Dec 2
  6. Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 Now $84.78 +36.90% settles Nov 17
  7. Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 Now $84.78 +41.65% ▲ +24.31% +25.47% vs SPY
  8. Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 Now $84.78 +34.29% ▲ +18.39% +21.66% vs SPY
  9. Aug 6, 202614w ago Press Release Bearish 7/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
  10. Aug 6, 202614w ago 424B5 Bearish 6/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 25m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026